• Masanori Komatsu, Osamu Shiono, Takahide Taguchi, Yasunori Sakuma, Goushi Nishimura, Daisuku Sano, Naoko Sakuma, Kenichiro Yabuki, Yasuhiro Arai, Masahiro Takahashi, Junichi Isitoya, and Nobuhiko Oridate.
• *Department of Otorhinolaryngology and Head and Neck Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan. komatsu3@yokohama-cu.ac.jp.
• Jpn. J. Clin. Oncol. 2014 May 1;44(5):416-21.

ObjectiveCompared with radiotherapy alone, concurrent chemoradiotherapy significantly improves survival rates for patients with squamous cell carcinoma of the head and neck. The aim of this study was to retrospectively evaluate the efficacy, toxicity and long-term prognosis of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil chemotherapy.MethodsA total of 140 patients were enrolled and evaluated. Patients were received two cycles of docetaxel, cisplatin and 5-fluorouracil chemotherapy (docetaxel [50 mg/m(2): Day 1], cisplatin [60 mg/m(2): Day 4] and continuous 5-fluorouracil [600 mg/m(2)/day: Days 1-5]) during definitive radiotherapy.ResultsThe overall response rate was 97.1%. The 3 and 5-year overall survival rates were 83.3 and 79.2%, respectively. The 3 and 5-year disease-specific survival rates were 84.2 and 80.0%, respectively. Among patients with laryngeal or hypopharyngeal carcinoma, the 5-year laryngectomy-free survival rate was 64.9%.ConclusionsConcurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil showed excellent survival and organ preservation rates for the patients with locally advanced squamous cell carcinoma of the head and neck.

32 keywords...

hide…